GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (LTS:0R6U) » Definitions » EBIT

4SC AG (LTS:0R6U) EBIT : €-7.33 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is 4SC AG EBIT?

4SC AG's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-3.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-7.33 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 4SC AG's annualized ROC % for the quarter that ended in Jun. 2024 was -1,244.66%. 4SC AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -53,117.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 4SC AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -10.19%.


4SC AG EBIT Historical Data

The historical data trend for 4SC AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG EBIT Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.82 -18.95 -9.63 -14.36 -8.12

4SC AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.32 -3.04 -4.64 -3.48 -3.85

Competitive Comparison of 4SC AG's EBIT

For the Biotechnology subindustry, 4SC AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 4SC AG's EV-to-EBIT falls into.



4SC AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-7.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG  (LTS:0R6U) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

4SC AG's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-7.894 * ( 1 - -0.2% )/( (0.763 + 0.508)/ 2 )
=-7.909788/0.6355
=-1,244.66 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

4SC AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.702/( ( (0.016 + max(-3.257, 0)) + (0.013 + max(-3.277, 0)) )/ 2 )
=-7.702/( ( 0.016 + 0.013 )/ 2 )
=-7.702/0.0145
=-53,117.24 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.161 + 0 + 0.272) - (3.576 + 0 + 0.114)
=-3.257

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.173 + 0 + 0.295) - (3.63 + 0 + 0.115)
=-3.277

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

4SC AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-7.332/71.935
=-10.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG EBIT Related Terms

Thank you for viewing the detailed overview of 4SC AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG Headlines

No Headlines